Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

BENCHMRK studies reveal activity of raltegravir in triple-class resistant HIV

March 8, 2007

TMC-278 meets 48-week endpoint in treatment-naive HIV patients

March 6, 2007

Pfizer reports phase III data for maraviroc

March 6, 2007

Maturation inhibitor PA-040 begins phase I study

March 1, 2007

Amazon Biotech preparing phase I/II studies for AMZ-0026

Feb. 28, 2007

GS-9137 completes phase II study in HIV

Feb. 27, 2007

Novel agents for HIV infection reported in recent patents

Feb. 26, 2007

Avexa reports progress with apricitabine

Feb. 26, 2007

IAVI applauds creation of Canadian HIV Vaccine Initiative

Feb. 23, 2007

Safety, absorption of TMC-120 assessed in women with and without HIV

Feb. 20, 2007

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...